Sunbird Bio

At Sunbird Bio, #AlzheimersAwarenessMonth is a time to reflect on the progress scientists and researchers are making every day in the detection and treatment of this devastating neurological disease, and look ahead to what we still have to accomplish.     Our CEO John McDonough shares why he believes the near-term future holds hope for those affected by #Alzheimer’s disease.     Access resources from Alzheimer's Foundation of America and learn why we #GoTeal during this important month: https://lnkd.in/gBRnmrg8   

At this year’s CTAD Clinical Trials on Alzheimer's Disease conference, we shared findings from our study evaluating our blood-based diagnostic’s capability to detect alpha synuclein aggregation in the brain, a hallmark of Parkinson’s disease and often found in people with Alzheimer’s disease. Learn more about our platform and data presented at #CTAD24 in this Clinical Trials Arena article: https://lnkd.in/ehgWc2G6 #innovation #biotechnews #Parkinsons

#NEWS: Today at #CTAD24 we announced new data from our blood-based diagnostic platform demonstrating its potential to detect Parkinson’s disease via extracellular vesicle-bound alpha synuclein proteins.    Stop by our presentation at the CTAD Clinical Trials on Alzheimer's Disease international conference in Madrid, Spain. Read more: https://lnkd.in/eAV5-yPc   #ParkinsonsDisease #AlzheimersDisease #diagnostics #biotechnews

#NEWS: We are partnering with The Global Alzheimer's Platform Foundation to explore the potential to improve the diagnosis of Alzheimer’s disease and related dementias through the Bio-Hermes-002 study.  This study compares blood-based and digital biomarkers that may help predict, diagnose and detect #Alzheimers disease across a broad range of races and ethnicities.  We’re proud to be part of this strategic #partnership. Read more here: https://lnkd.in/gBB5pb_P #diagnostics #innovation #biotechnews

"I want to showcase how flexible the [Sunbird Bio] platform really is." Our head of innovation and scientific co-founder, Dr. Nicholas Ho, recently spoke with Jessica Kim Cohen at 360Dx about our diagnostic technology and its potential to detect disease-specific proteins across a diverse range of neurological diseases with a simple blood draw. Read more to learn how Sunbird Bio is on track to become a global leader in blood-based #diagnostics and address significant research and clinical gaps: https://lnkd.in/eUeh22a2   #innovation #healthcare #pharmanews #biopharma

#NEWS: Today we announced the closing of an additional $14 million financing round backed by two new investors.  This additional funding will help us expand the development of our proprietary blood-based diagnostic platform, which has demonstrated potential to support earlier, more accurate diagnosis and treatment of Alzheimer’s disease, Parkinson’s disease and other neurological disorders.  Our Executive Chair and CEO, John McDonough, puts it best: “We’re even better positioned to positively impact the millions of people globally who are affected by devastating neurological diseases.”  Read the full release here: https://bit.ly/3zRD4OC #funding #diagnostics #Alzheimers #Parkinsons #investors

Improving outcomes for people with neurological disorders starts with better ways to diagnose patients. As research continues to uncover new biomarkers for #Alzheimers, #Parkinsons and other disorders, we’re working to develop blood-based diagnostics that have the potential to empower patients, researchers and clinicians with unparalleled insights not available from current tests.  Learn more about the range of biomarkers we’re exploring to detect Alzheimer’s disease and other neurological disorders:https://lnkd.in/esmps2zf #innovation #diagnostics #alzheimers #healthcare

For #WorldAlzheimersMonth, we are supporting Alzheimer's Disease International's mission to raise awareness and challenge the stigma that persists around Alzheimer’s disease.    This year’s theme, “Time to Act on Alzheimer’s,” reminds us of the tremendous, growing need for more reliable and sensitive diagnostic tests to accelerate drug development and enhance patient care.    Learn more about World Alzheimer’s Month: https://lnkd.in/eGsXmt4K  #TimeToActOnAlzheimers #alzheimers

On #WorldAlzheimersDay, and every day, we remain steadfast in our commitment to developing non-invasive technologies that have the potential to empower patients, researchers and clinicians in the diagnosis of #Alzheimers disease.     At Sunbird Bio, we believe that earlier diagnosis can lead to improved patient outcomes. Learn more about signs of Alzheimer’s disease from the Alzheimer's Association®: https://lnkd.in/eGsXmt4K  

Our blood-based #diagnostic platform uniquely and directly detects, measures and assesses proteins that indicate the presence and activity of multiple neurological diseases.     As our CEO and executive chair John McDonough explains, our technology has the potential to overcome barriers associated with standard diagnostic tests for unparalleled detection of neurological diseases.     Read what makes Sunbird Bio unique: https://lnkd.in/ghx9B3VY #innovation #alzheimers #tau #Parkinsons #healthcare